National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Macitentan is indicated as monotherapy or in combination, for the long term treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III.

 Rapid Review

Commenced Completed Outcome
10/01/2014 27/01/2014 Full Pharmacoeconomic Evaluation Not Recommended